Drug intelligence / Profile preview

whole glucan particle

Development stage
Unknown
Lead developer
HiberCell
Modality
Nanoparticles → Drug Delivery Systems
Administration
Oral, Intravenous
01

Overview

Whole glucan particles (WGP) are purified, hollow, porous spheres composed primarily of beta-1,3/1,6-glucan derived from the cell wall of the yeast *Saccharomyces cerevisiae*. WGP acts as a potent immune modulator by serving as a pathogen-associated molecular pattern (PAMP) that is recognized by the Dectin-1 (CLEC7A) receptor on myeloid cells, including macrophages, dendritic cells, and neutrophils. Upon binding, WGP triggers innate immune activation, characterized by the production of pro-inflammatory cytokines and the reprogramming of immunosuppressive myeloid-derived suppressor cells (MDSCs) into an M1-like anti-tumor phenotype. In clinical oncology, WGP is investigated as an adjuvant to enhance the efficacy of monoclonal antibodies and checkpoint inhibitors (such as anti-PD-1 or anti-TIGIT) by priming the innate immune system to coordinate a more robust adaptive T-cell response against tumors.

Brand names
Wellmune
Other names
Yeast beta-glucanParticulate beta-glucanSaccharomyces cerevisiae beta-glucan
02

Targets

CLEC7A (Dectin-1)

Beyond the preview

Go deeper on whole glucan particle.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on whole glucan particle.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call